Phase IV safety evaluation of voclosporin in lupus nephritis patients using the FAERS database for a 42-month period (2021 – 2024)
Int. Journal of Clinical Pharmacology and Therapeutics · 2025
DOI: 10.5414/cp204726 ↗Kurz gefasst
Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2025. Verfasst von Bo Gu und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Lupus Nephritis, Cyclosporine, Adverse Drug Reaction Reporting Systems, Calcineurin Inhibitors.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Gu, B., Lv, B., & Tang, J. (2025). Phase IV safety evaluation of voclosporin in lupus nephritis patients using the FAERS database for a 42-month period (2021 – 2024). Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204726
Vancouver
Gu B, Lv B, Tang J. Phase IV safety evaluation of voclosporin in lupus nephritis patients using the FAERS database for a 42-month period (2021 – 2024). Int. Journal of Clinical Pharmacology and Therapeutics. 2025. doi:10.5414/cp204726
BibTeX
@article{Gu2025,
author = {Gu, Bo and Lv, Bing and Tang, Jia},
title = {Phase IV safety evaluation of voclosporin in lupus nephritis patients using the FAERS database for a 42-month period (2021 – 2024)},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2025},
doi = {10.5414/cp204726}
}
EUVIMED